ALBUQUERQUE, N.M., July 9 /PRNewswire-FirstCall/ -- Biomoda, Inc. , a New Mexico-based biotech company, http://www.biomoda.com, focusing on early-stage lung cancer detection, today updates investors on corporate activities regarding patents, clinical studies and initiatives in progress of interest to investors.
John Cousins, President of Biomoda, commented, “We are the first company to develop an early detection test for lung cancer. Over the next six years in the US alone one million people will perish as a result of this disease. Biomoda has the technology to provide an early diagnosis for lung cancer at the cellular level, which is an achievement that no other company can lay claim.”
“As Biomoda moves forward, we expect our non-invasive cellular diagnostic assay to become the industry standard test for this hideous disease. In essence it could easily complement current technologies such as CT Scans and biopsies which, in most cases, do not detect lung cancer until Stages II-IV.”
“It is important to realize that detection of lung cancer in Stage I can potentially result in an increase of 75 percent in the five-year survivability rate. Thus, we would be increasing the survivability rate from the fifteenth percentile to the ninetieth percentile.”
“Biomoda is currently focusing on lung cancer, however in-house studies performed in our labs at Kirtland AFB have lead to an indication that this technology could be employed in the detection of other cancers.”
The company also provided an overview of progress in the following areas: Patents:
The company has filed four patent applications with the US Patent Office in Washington, DC.
To date one patent has been granted and three are pending. The company also exclusively licenses one patent from Los Alamos National Laboratories. By securing these patents the company is enabling itself to move forward with the rapid development of its technology without jeopardizing future licensing and world-wide commercialization of its cutting-edge technology.
Biomoda’s technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope.
The company will continue to provide updates on new patents filed and patents granted.
Legislative Initiatives:
The company has undertaken a grass-roots approach to providing information on its lung cancer detection technology to Members of Congress and state legislatures.
These efforts were undertaken in order to attain funds allocated at the Federal and State level for smoking-related cancer research.
The company previously announced that it was focusing on testing military veterans for clinical studies of its early detection technology because veterans are 25% more likely to succumb to lung cancer than the general public. The company intends to continue with these legislative meetings and update shareholders as results of such initiatives as is prudent.
Independent Research Validation:
Within the next 6 - 12 months the company expects to announce results of the first independent clinical research study. This study is currently underway with one of the nation’s foremost research and medical centers. This study will provide empirical data needed for the validation of the technology and consequently spur the licensing of the cancer detection assay to medical centers and health care operations around the globe.
About Biomoda, Inc.
Biomoda, Inc. , is a biopharmaceutical company focusing on early Cancer detection technology. Biomoda’s non-invasive cell-targeting technology is globally patented for the detection of pre-cancerous and cancerous conditions in all human tissue. This technology, based on a compound called Tetrakis Carboxy Phenyl Porphine (TCPP), was developed at Los Alamos National Laboratories. Biomoda obtained a worldwide exclusive license to the TCPP technology from Los Alamos National Laboratories, and began new research broadening the scope of the original patent and technology.
For more information about Biomoda, please visit the company’s website at http://www.biomoda.com.
Forward Looking Statements:
This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as “anticipate,” “believe,” “expect,” “future,” “intend,” “plan,” and similar expressions to identify forward-looking statements. Forward-looking statements include, without limitation, our ability to increase income streams, to grow revenue and earnings, and to obtain additional patents and strategic partnerships or research projects. These statements are only predictions and are subject to certain risks, uncertainties and assumptions, which are identified and described in the Company’s public filings with the Securities and Exchange Commission.
Biomoda, Inc.
CONTACT: John Cousins of Biomoda, Inc., +1-505-821-0875
Web site: http://www.biomoda.com//
